L-Deprenil, A Selective Monoamine Oxidase Type B Inhibitor, in the Treatment of Depression: A Double Blind Evaluation

1983 ◽  
Vol 142 (5) ◽  
pp. 508-511 ◽  
Author(s):  
J. Mendlewicz ◽  
M. B. H. Youdim
Keyword(s):  
Monoamine Oxidase ◽  
Clinical Improvement ◽  
Positive Relationship ◽  
Controlled Study ◽  
Type B ◽  
Double Blind ◽  
Mao B ◽  
Mao Inhibition ◽  
Platelet Mao ◽  
Treatment Of Depression

SummaryIn a double blind controlled study, 14 affectively ill patients (2 bipolars, 12 unipolars) were randomly allocated to L-Deprenil treatment (an irreversible selective MAO-B inhibitor without “cheese effect”) and 13 patients (3 bipolars, 10 unipolars) to placebo only. Patients on L-Deprenil showed a significantly greater clinical improvement than placebo patients. A positive relationship was found between clinical improvement and degree of platelet MAO inhibition in patients treated with L-Deprenil.

THE EVALUATION OF RACEMIC EPINEPHRINE IN THE TREATMENT OF INFECTIOUS CROUP

PEDIATRICS ◽  
1973 ◽  
Vol 52 (1) ◽  
pp. 52-55
Author(s):  
H. Garry Gardner ◽  
Keith R. Powell ◽  
Vernon J. Roden ◽  
James D. Cherry
Keyword(s):  
Clinical Improvement ◽  
Direct Effect ◽  
Retrospective Review ◽  
Therapeutic Regimen ◽  
Controlled Study ◽  
Double Blind ◽  
Therapeutic Procedures ◽  
Duration Of Hospitalization

The effectiveness of racemic epinephrine in the treatment of croup was evaluated by a retrospective review, a prospective protocol, and a controlled study. Although the majority of children who were treated with racemic epinephrine and evaluated prospectively had significant immediate clinical improvement, the therapeutic regimen did not seem to affect the overall duration of hospitalization or the incidence of tracheotomy during the study period. Ten of the 20 children who participated in the double-blind controlled study had significant improvement; five received racemic epinephrine and five received the placebo. These findings suggest that the apparent effectiveness of racemic epinephrine might be due to the nebulization of moisture rather than a direct effect of the drug. The present study points out the critical need for controlled studies in the evaluation of therapeutic procedures in the treatment of croup.

scholarly journals Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson’s disease: a multiple treatment comparison meta-analysis

2020 ◽  
Vol 76 (12) ◽  
pp. 1731-1743
Author(s):  
Caroline D. Binde ◽  
Ingunn F. Tvete ◽  
Jørund I. Gåsemyr ◽  
Bent Natvig ◽  
Marianne Klemp
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Monoamine Oxidase ◽  
Comparative Effectiveness ◽  
Dopamine Agonists ◽  
Relative Effectiveness ◽  
Type B ◽  
Mao B ◽  
Treatment Comparison ◽  
Monoamine Oxidase Type B

Abstract Purpose To investigate the comparative effectiveness of dopamine agonists and monoamine oxidase type-B (MAO-B) inhibitors available for treatment of Parkinson’s disease. Methods We performed a systematic literature search identifying randomized controlled trials investigating 4 dopamine agonists (cabergoline, pramipexole, ropinirole, rotigotine) and 3 MAO-B inhibitors (selegiline, rasagiline, safinamide) for Parkinson’s disease. We extracted and pooled data from included clinical trials in a joint model allowing both direct and indirect comparison of the seven drugs. We considered dopamine agonists and MAO-B inhibitors given as monotherapy or in combination with levodopa. Selected endpoints were change in the Unified Parkinson’s Disease Rating Scale (UPDRS) score, serious adverse events and withdrawals. We estimated the relative effectiveness of each dopamine agonist and MAO-B inhibitor versus comparator drug. Results Altogether, 79 publications were included in the analysis. We found all the investigated drugs to be effective compared with placebo when given as monotherapy except safinamide. When considering combination treatment, the estimated relative effects of selegiline, pramipexole, ropinirole, rotigotine, cabergoline, rasagiline and safinamide were 2.316 (1.819, 2.951), 2.091 (1.889, 2.317), 2.037 (1.804, 2.294), 1.912 (1.716, 2.129), 1.664 (1.113, 2.418), 1.584 (1.379, 1.820) and 1.179 (1.031, 1.352), respectively, compared with joint placebo and levodopa treatment. Conclusions Dopamine agonists were found to be effective as treatment for Parkinson’s disease, both when given as monotherapy and in combination with levodopa. Selegiline and rasagiline were also found to be effective for treating Parkinson’s disease, and selegiline was the best option in combination with levodopa among all the drugs investigated.

scholarly journals Platelet Monoamine Oxidase B Activity in “de novo” and L-Dopa Treated Parkinsonian Patients and Controls

1998 ◽  
Vol 25 (3) ◽  
pp. 249-251 ◽  
Author(s):  
Wilfried Kuhn ◽  
Thomas Müller ◽  
Anja Gerstner ◽  
Regina Winkel ◽  
Mario E. Goetz
Keyword(s):  
Monoamine Oxidase ◽  
De Novo ◽  
Enzymatic Assay ◽  
Monoamine Oxidase B ◽  
Mao B ◽  
Levodopa Treatment ◽  
Platelet Mao ◽  
Platelet Monoamine Oxidase ◽  
Age And Sex

ABSTRACT:Objective:Previous studies demonstrated controversial results regarding monoamine oxidase B (MAO-B) activity in platelets in the periphery in parkinsonian patients (PD).Subjects and Methods:Therefore we determined platelet MAO-B activity in three age- and sex-matched groups of 17 untreated, so called “de novo” patients with Parkinson's disease (PD), 17 parkinsonian patients, receiving levodopa, and 17 controls by a radio enzymatic assay.Results:No significant differences of MAO-B activity appeared.Conclusion:This result suggests that phenotypic determination of MAO-B activity in platelets may not be used as peripheral marker in PD and that levodopa treatment does not alter MAO-B activity in the periphery.

A Double-Blind, Placebo-Controlled Study of Fluoxetine in Depressed Patients With Alzheimer's Disease

2001 ◽  
Vol 13 (2) ◽  
pp. 233-240 ◽  
Author(s):  
Gustavo M. Petracca ◽  
Eran Chemerinski ◽  
Sergio E. Starkstein
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Rating Scale ◽  
Functional Independence ◽  
Controlled Study ◽  
Consecutive Series ◽  
Hamilton Depression Scale ◽  
Double Blind ◽  
Treatment Of Depression ◽  
Efficacy Measures

Objective: To examine the efficacy of fluoxetine in the treatment of depression in patients with probable Alzheimer's disease (AD). Methods: This double-blind, parallel-design study included a consecutive series of 41 AD subjects meeting DSM-IV criteria for major or minor depression who were randomized to receive fluoxetine (up to 40 mg/day) or identical-appearing placebo. All patients received biweekly evaluations consisting of the Hamilton Depression Scale (HAM-D) and the Clinical Global Impression as primary efficacy measures, and the Mini-Mental State Exam, Hamilton Rating Scale for Anxiety, and the Functional Independence Measure as secondary efficacy measures. Results: Complete remission of depression was found in 47% of subjects treated with fluoxetine and in 33% of subjects treated with placebo. Both the fluoxetine and the placebo groups showed a significant decline in HAM-D scores over time, but the magnitude of mood improvement was similar for both groups. Fluoxetine was well tolerated, and most side effects were mild. Conclusion: Fluoxetine treatment for depression in AD did not differ significantly from treatment with placebo. Our study also confirms the presence of a placebo effect in the treatment of depression in AD.

Pharmacological Treatment of Depression in Cancer Patients

1996 ◽  
Vol 169 (4) ◽  
pp. 440-443 ◽  
Author(s):  
Kees Van Heeringen ◽  
Milana Zivkov
Keyword(s):  
Cancer Patients ◽  
Rating Scale ◽  
Controlled Study ◽  
Systematic Research ◽  
Cancer Stage ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Patients With Cancer ◽  
Treatment Of Depression ◽  
Hamilton Rating Scale

BackgroundDepression has a reported mean prevalence of 24% in patients diagnosed with cancer. However, little systematic research on the efficacy of antidepressants in patients with cancer has been performed.MethodThe efficacy and safety of mianserin were studied in 55 depressed women with breast cancer (stage I or II and without known metastases), in a randomised, double-blind, six-week, placebo-controlled study.ResultsStatistically significant differences in the decrease in score from baseline on the Hamilton Rating Scale for Depression and the number of responders, favouring mianserin, were present after 28 and 42 days of treatment Significantly more placebo-treated patients prematurely terminated the study due to lack of efficacy while the safety profile of mianserin was similar to that of placebo.ConclusionsTreatment with mianserin resulted in a significant improvement in depressive symptoms in cancer patients, and was well tolerated.

Sign in / Sign up

Export Citation Format

Share Document